Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | GFH018 + Toripalimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GFH018 | GFH-018|GFH 018 | TGFBR1 inhibitor 15 | GFH018 inhibits TGFBR1, leading to decreased downstream signaling, and potentially resulting in modulation of immune response, decreased tumor cell migration, reduced angiogenesis, and antitumor activity (Cancer Res 2019;79(13 Suppl):Abstract nr 3072). | |
Toripalimab | JS001|JS-001|TAB001 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86 | Toripalimab (JS001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293, PMID: 32321714). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Recruiting | 1 |